热景生物：2025年第五次临时股东会决议公告

Core Viewpoint - The announcement by Rejuve Bio indicates significant corporate actions involving capital increase and equity transfer related to ShunJing Pharmaceutical, along with the implementation of an equity incentive plan and related party transactions [2] Group 1: Corporate Actions - Rejuve Bio's fifth extraordinary general meeting in 2025 approved a proposal for capital increase and equity transfer to ShunJing Pharmaceutical [2] - The company also approved a proposal for joint investment in YaoJing Gene with related parties, indicating strategic collaboration and investment initiatives [2]